{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:05:30Z","timestamp":1774566330055,"version":"3.50.1"},"reference-count":12,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["fertstertreports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["F&S Reports"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.xfre.2025.11.004","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T10:43:23Z","timestamp":1763635403000},"page":"81-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Possible drug reaction with eosinophilia and systemic symptoms after spironolactone therapy for clinical hyperandrogenism: a case report"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1876-1234","authenticated-orcid":false,"given":"Sandy","family":"Hoang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Strom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen M.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xfre.2025.11.004_bib1","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.mcna.2021.06.008","article-title":"Practical approach to hyperandrogenism in women","volume":"105","author":"Sharma","year":"2021","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.xfre.2025.11.004_bib2","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1093\/humrep\/dew218","article-title":"The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis","volume":"31","author":"Bozdag","year":"2016","journal-title":"Hum Reprod"},{"key":"10.1016\/j.xfre.2025.11.004_bib3","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1093\/ejendo\/lvad096","article-title":"International PCOS Network. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"189","author":"Teede","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.xfre.2025.11.004_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102162","article-title":"Efficacy and safety of anti-androgens in the management of polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials","volume":"63","author":"Alesi","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.xfre.2025.11.004_bib5","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xfre.2025.11.004_bib6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/00015550310005915","article-title":"Drug-induced eosinophilia and multisystemic failure with positive patch-test reaction to spironolactone: DRESS syndrome","volume":"84","author":"Ghislain","year":"2004","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.xfre.2025.11.004_bib7","first-page":"E53","article-title":"A rare case of acne medication-induced drug reaction with eosinophilia and systemic symptoms","volume":"121","author":"Hamel","year":"2022","journal-title":"WMJ"},{"key":"10.1016\/j.xfre.2025.11.004_bib8","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.4103\/idoj.IDOJ_279_20","article-title":"DRESS syndrome secondary to spironolactone with atypical presentation","volume":"11","author":"Bains","year":"2020","journal-title":"Indian Dermatol Online J"},{"key":"10.1016\/j.xfre.2025.11.004_bib9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/cod.13073","article-title":"Drug reaction with eosinophilia and systemic symptoms caused by spironolactone: case report","volume":"79","author":"Fernandes","year":"2018","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.xfre.2025.11.004_bib10","article-title":"Linear IgA bullous dermatosis attributable to the use of spironolactone: a case report","volume":"15","author":"Philip","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.xfre.2025.11.004_bib11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2500\/108854186779045584","article-title":"Readministration of spironolactone in the spironolactone-intolerant patient","volume":"7","author":"Greenberger","year":"1986","journal-title":"N Engl Reg Allergy Proc"},{"key":"10.1016\/j.xfre.2025.11.004_bib12","series-title":"StatPearls","article-title":"Erythema multiforme","author":"Hafsi","year":"2025"}],"container-title":["F&S Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666334125001588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666334125001588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T20:44:48Z","timestamp":1770756288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666334125001588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2666334125001588"],"URL":"https:\/\/doi.org\/10.1016\/j.xfre.2025.11.004","relation":{},"ISSN":["2666-3341"],"issn-type":[{"value":"2666-3341","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Possible drug reaction with eosinophilia and systemic symptoms after spironolactone therapy for clinical hyperandrogenism: a case report","name":"articletitle","label":"Article Title"},{"value":"F&S Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xfre.2025.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Society for Reproductive Medicine.","name":"copyright","label":"Copyright"}]}}